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Background: Lack of adherence to medication is a trigger 
of graft rejection in solid-organ transplant (SOT) recipients.  
Objective: This exploratory study aimed to assess 
whether a biopsychosocial evaluation using the 
INTERMED instrument before transplantation could 
identify SOT recipients at risk of suboptimal post-
transplantation adherence to immunosuppressant drugs. 
We hypothesized that complex patients (INTERMED>20) 
might have lower medication adherence than noncomplex 
patients (INTERMED≤20).  
Methods: Each patient eligible for transplantation at the 
University Hospital of Lausanne, Switzerland, has to 
undergo a pre-transplantation psychiatric evaluation. In 
this context the patient was asked to participate in our 
study. The INTERMED was completed pre-transplantation, 
and adherence to immunosuppressive medication was 
monitored post-transplantation by electronic monitors for 
12 months. The main outcome measure was the 
implementation and persistence to two calcineurin 
inhibitors, cyclosporine and tacrolimus, according to the 
dichotomized INTERMED score (>20 or ≤20). 
Results: Among the 50 SOT recipients who completed the 
INTERMED, 32 entered the study. The complex (N=11) 
and noncomplex patients (N=21) were similar in terms of 
age, sex and transplanted organ. Implementation was 
94.2% in noncomplex patients versus 87.8% in complex 
patients (non-significant p-value). Five patients were lost 
to follow-up: one was non-persistent, and four refused 
electronic monitoring. Of the four patients who refused 
monitoring, two were complex and withdrew early, and two 
were noncomplex and withdrew later in the study. 
Conclusion: Patients identified as complex pre-transplant 
by the INTERMED tended to deviate from their 
immunosuppressant regimen, but the findings were not 
statistically significant. Larger studies are needed to 
evaluate this association further, as well as the 
appropriateness of using a nonspecific biopsychosocial 
instrument such as INTERMED in highly morbid patients 
who have complex social and psychological 
characteristics. 
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INTRODUCTION 
Psychosocial problems, such as anxiety and 
depression
1
, emotional distress
2,3
, past alcohol and 
substance abuse
4
 as well as social isolation
5
 are 
common in transplant candidates and contribute to 
post-transplant management complexity.
6,7
 These 
factors impact health-related quality of life (HRQOL) 
and biomedical outcomes.
7-9
 Methods to proactively 
identify transplant candidates who are at particular 
risk of needing complex post-transplant care have 
to be developed. However, the effectiveness of 
instruments such as the Psychological Assessment 
of Candidates for Transplantation (PACT)
10
, the 
Transplant Evaluation Rating Scale (TERS)
11
 or the 
INTERMED
12,13
  in identifying patients at risk for 
unfavourable biomedical outcomes after 
transplantation has not been shown. Only the 
Stanford Integrated Psychosocial Assessment for 
Transplantation (SIPAT)
14,15
 has found a significant 
association between psychosocial pre-transplant 
assessment, rejection episodes and medical 
hospitalizations. The specific question whether 
there is an association between pre-transplant 
assessment and medication adherence was also 
investigated in this study. The relationship between 
high SIPAT scores and nonadherence suggested a 
trend, but was not statistically significant.
14
 
We have previously reported the utility of the 
INTERMED for describing liver transplant 
candidates from a biopsychosocial perspective and 
identifying complex patients with mood disturbances 
and reduced HRQOL
16
; liver transplant patients 
were the sole common organ group investigated in 
all participating centres of the study and were 
therefore chosen as studied population. Among 
these liver transplant candidates, 38% were 
detected as complex according to the INTERMED 
criteria. The INTERMED
17,18
 is a screening 
instrument to identify patients with multiple care 
needs. It is based on the concept of case 
complexity, which is determined by diagnosis as 
well as by a variety of other parameters that 
influence patient management and prognosis, such 
as chronicity and severity of illness, limitations in 
daily life, psychiatric comorbidity and social 
vulnerability. 
According to a review, prevalence of reported 
medication nonadherence is around 28% in kidney 
transplantation.
19
 Early medication adherence 3-
months post renal transplantation varies between 
93.5% and 84% depending on the complexity of the 
immunosuppressant treatment (from once-daily 
regimen to 4 doses per day).
20
 Immunosuppressant 
medication nonadherence, which is partly 
influenced by psychosocial determinants, is an 
important trigger of acute rejection and graft loss in 
solid-organ transplant (SOT) recipients.
19-22
 
Nonadherence contributes to 20% of late acute 
rejection episodes and 16% of graft losses in kidney 
transplantation.
19
 In another study in kidney 
transplant recipients, graft loss due to 
nonadherence represents 48% of death-censored 
graft failures beyond 2 years.
21
 Hazard risk of graft 
loss and death increases significantly with fair (HR: 
1.63; 95%CI: 1.37-1.93; p<0.0001) or poor (HR: 
1.80; 95%CI: 1.52-2.13; p<0.0001) adherence in 
comparison to good and excellent adherence as 
measured by pharmacy refills in kidney 
transplantation.
22
 In the Swiss Cohort Transplant 
study, De Geest et al. reported that self-reported 
pretransplant medication nonadherence was 
significantly associated with post-transplant 
immunosuppressive medication nonadherence 
among kidney, liver, lung and heart transplant 
groups (OR: 3.10; 95%CI: 2.29-4.21).
23
 Main 
variables associated with nonadherence were 
young age
19,21,22
, social isolation and poor health 
literacy
19
, depression
24
, non-white recipients
21
 but 
also forgetfulness/interruption of daily routine.
25
 
Based on the existing evidence in the literature, we 
sought to determine whether a pre-transplant 
INTERMED evaluation can identify patients with low 
medication adherence post-transplantation. We 
therefore monitored medication adherence and its 
association with baseline INTERMED scores. 
 
METHODS  
The study was approved by the local Ethics 
Committee (Commission d’Ethique de la Recherche 
Clinique, Sous-Commission III, session may 22
nd
, 
2002, protocol: 98/02) , and all the participants gave 
written consent. 
Our study reports on a subsample of patients in the 
aforementioned longitudinal European INTERMED 
project, referred to in the introduction, which 
assessed the biopsychosocial profiles of transplant 
candidates and the prevalence of case 
complexity.
13,16
 For the multicentre European 
INTERMED project, the Lausanne patients were 
recruited prospectively during the pre-transplant 
psychiatric evaluation. Every patient who presented 
to the Transplantation Centre of Lausanne 
University Hospital (CHUV) for SOT was considered 
for inclusion, except those who could not be 
evaluated because of severe cognitive disturbances 
(exclusion criteria). 
For the Lausanne, one-centre substudy, the 
inclusion criteria applied during the post-transplant 
hospital stay, were as follows: to take part in the 
European project in Lausanne and to have 
benefited from a SOT. Exclusion criteria were 
deaths during post-SOT hospitalization, patients 
refusing to use the medication electronic monitor 
and logistic problems precluding inclusions. In this 
population, immunosuppressant medication 
adherence was measured by electronic monitors 
during the first 12 months post-transplant. Baseline 
data were collected between 2003 and 2007, and 
patient follow-up was completed in 2009.  
The INTERMED, the first empirically based 
instrument to link case and care complexity
17,18
, is a 
visual, action-oriented decision-support tool for the 
assessment of biopsychosocial health risks and 
health needs. When used by trained health care 
professionals from different backgrounds, the 
validity and reliability of the tool has been 
demonstrated in a variety of medical 
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populations
17,18,26,27
, including liver transplant 
recipients.
16
 The utility of the INTERMED has been 
demonstrated for detecting complex, medically ill 
patients at risk for poor HRQOL and decreased 
response to medical treatment
28
; it has also proven 
to be a case-finder for early and beneficial 
psychosocial interventions.
29-31
 The INTERMED 
(see Table 1) classifies information into four 
domains: biological, psychological, social and health 
care. Each domain contains two variables related to 
the patient’s past and current situations and one 
variable about the patient’s prognosis. The variables 
are assessed by review of the medical chart and a 
subsequent 20 minute semi-structured patient 
interview. They are scored from 0 (no vulnerability / 
needs) to 3 (severe vulnerability / needs); for each 
variable, anchor points are defined in a glossary to 
facilitate scoring. The maximum score for the 20 
variables is therefore 60 (range 0 – 60), and the cut-
off score for qualifying as a complex patient is set 
>20.
28
 The original English version of the 
INTERMED has been translated and validated in 
different languages
18,26
 and is used in routine 
clinical practice.
31
  
The Medication Event Monitoring System (MEMS) 
is a tool to measure medication adherence. It 
consists of an electronic device which records and 
stores the date and time of each opening of the pill 
container (MEMS TrackCapTM, MWV Switzerland 
Ltd.). Compared to other methods for assessing 
medication adherence, such as questionnaires or 
plasma drug concentrations, electronic monitors are 
the only tools which produce reliable, dynamic and 
“real-time” information on how medication is taken 
by the patient each day.
32-36
  
To increase reliability, electronic data were 
reconciled according to an operational manual 
described elsewhere.
37,38
 Reconciliation with the pill 
count and the case report form allowed us to add 
confirmed pocket doses to the electronic adherence 
data (i.e., a dose, which the patient takes out of the 
pillbox to take it later). 
Procedure 
The face-to-face interview based on the INTERMED 
was part of the European project. It was conducted 
by the two first authors of the study (LM, GL), who 
both worked in the Psychiatric Liaison Service of 
Lausanne University Hospital; they were familiar 
with the INTERMED and the standard protocol for 
using the instrument. 
The electronic monitoring of adherence to the 
immunosuppressant drugs was conducted by the 
pharmacists (AN, VS, MPS) in the Department of 
Ambulatory Care & Community Medicine at the 
University Hospital of Lausanne; these pharmacists 
run a medication adherence clinic and have 
research experience with the use of electronic 
monitors. 
After the patients were enrolled in the study by the 
physician, the patients were referred to the 
pharmacists who dispensed the prescribed 
calcineurin inhibitor-based medication (cyclosporine 
25, 50 and 100 mg or tacrolimus 0.5, 1 and 5 mg) in 
the electronic monitors every month for 12 months 
post-transplantation and explained the correct use 
of the electronic device. Each dosage was delivered 
in separate MEMS according to good 
pharmaceutical practices; electronic data were 
downloaded monthly and shown as feedback to the 
patients without any further systematic intervention. 
This monthly feedback represents standard care in 
this centre at this time. Additional 
immunosuppressant medications were not 
electronically monitored but were delivered 
according to standard care. 
All dosages per patient and day were compiled to 
obtain the quantity of each drug taken by day 
compared to the expected dosage (e.g., patient X 
took 75 mg cyclosporine (Drug taken) on day Y 
instead of 175 mg (Drug expected)). All changes in 
drug dosages were taken into account; changes 
occurred frequently during the 12 months post-
transplantation. 
Statistical analysis 
Sociodemographic and medical variables and 
INTERMED scores were compared using two-tailed 
chi-squared tests for categorical data and Mann-
Whitney U Tests for continuous data. A two-sided p-
value of <0.05 was used to determine statistical 
significance. For statistical analysis, SPSS, SAS 
and S-Plus were used. 
Immunosuppressant medication adherence and 
intention-to-treat analysis was performed according 
to two previously described definitions: persistence 
and implementation.
39
 Persistence is defined as the 
time from initiation of a studied treatment until 
discontinuation as determined by electronic 
adherence monitoring. Patients who stopped 
cyclosporine/tacrolimus were considered to be non-
persistent. Patients whose cyclosporine/tacrolimus 
prescriptions were changed were considered to be 
 
Table 1. INTERMED domains and variables 
Domains History Current state Prognoses 
Biological 
Chronicity Severity of illness 
Complications and life threat 
Diagnostic uncertainty Clarity of diagnostic profile 
Psychological 
Restrictions in coping Treatment resistance 
Mental health threat Premorbid level of psychiatric 
dysfunctioning 
Severity of psychiatric symptoms 
Social 
Family disruption Residential instability 
Social vulnerability 
Impairment of social support Impairment of social integration 
Health care 
Intensity of prior treatment 
Organizational complexity at 
admission or referral 
Care needs 
Prior treatment experience 
Appropriateness of admission or 
referral 
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persistent. If patients stopped the study but kept 
taking their cyclosporine/tacrolimus, they were 
considered to be persistent. 
Implementation was defined as the percentage of 
persistent patients who did not deviate from the 
prescribed medication regimen. For each patient, 
implementation data were summarized in a 
sequence of binary data indicating yes or no to the 
question of whether the patient had taken all the 
medications as prescribed by the physician on day j 
(1 = correct number of daily opening(s) of all 
electronic monitors; 0 = less daily openings than 
prescribed). In case of hospitalization, patients did 
not use the electronic monitors systematically. As 
they got their immunosuppressant from the hospital, 
these periods contained non-detected adherence 
data. Therefore, these periods were described as 
non-monitored and censored from the analysis. A 
logistic generalized estimating equation (GEE) 
model was implemented to analyse the resulting 
longitudinal binary data.
40
 GEE is the method of 
choice for analysing data with repeated measures 
for each patient; this method accounts for the 
interindividual variability of the measures and can 
address unbalanced data due to missing values. 
Persistence and implementation were described in 
the 2 groups according to each patient’s 
INTERMED score (>20 or ≤20). 
 
RESULTS  
A total of 52 SOT recipients were approached, all of 
whom were previously enrolled in the European 
project (see Figure 1). Median time between the 
completion of the INTERMED and the SOT was 335 
days (Quartiles 25,75: 176, 573; min-max: 28-
1199). From that group, 32 patients were included 
in this study and monitored by MEMS, 22 patients 
were prescribed tacrolimus twice a day and 10 
cyclosporine twice a day at inclusion. Twenty-seven 
patients completed follow up and were followed for 
a mean of 332 days. 
The patients who were included (N=32) and 
excluded (N=20) did not differ with regard to age, 
sex, and type of organ to be transplanted (Table 2). 
Because all patients completed the INTERMED 
baseline assessment, we were able to compare the 
INTERMED scores between included and excluded 
patients, and no differences between the two 
groups were found. However, excluded patients 
tended to show a higher, meaning worse, 
psychological score (p=0.069).  
The sociodemographic and clinical comparisons of 
the included complex (INTERMED>20) and non-
complex (INTERMED≤20) patients based on the 
INTERMED are summarized in Table 3. The only 
statistically significant difference was that complex 
patients were more likely to be unemployed (p 
0.037). Regarding the mean scores in the four 
domains of the INTERMED, complex patients had 
higher scores in every domain when compared to 
non-complex patients. Differences were more 
pronounced for psychological and social domains 
than for health care and biological domains (Table 
3). 
Regarding medication adherence, implementation 
was 94.2% in non-complex patients versus 87.8% in 
complex patients (p 0.274) (see Figure 2). In terms 
of medication persistence, only one patient was 
strictly non-persistent; one member of the non-
complex group discontinued after 171 days and 
died afterwards. Four patients withdrew; two 
Transplantation 
Exclusions 
(N = 20) 
Logistic problems (N = 16) 
Refusal of MEMS (N = 1) 
Death (N = 3) 
SOT recipients of European project 
between 2003-2009 and assessed with INTERMED 
during waiting time for TX  
(N = 52) 
During  
Post-transplant 
hospital stay 
Inclusions 
Medication Event Monitoring System (MEMS) (N = 32) 
(22 with tacrolimus and 10 with cyclosporine) 
Drop-outs and death  
(N = 5) 
Refusal of MEMS during 
study (N = 4) 
Death (N = 1) 
12-month period 
post-transplantation Follow up (N = 27) 
Figure 1. Flow diagram of participants of the study 
SOT = Solid Organ Transplantation, TX = Transplantation   
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complex patients withdrew early (at 24 and 29 days) 
because of noncompliance with the use of the 
electronic monitors, and because of global refusal of 
proposed care, respectively. Two non-complex 
patients withdrew later in the study (at 155 and 168 
days), both because of noncompliance with the use 
of the electronic monitors. 
 
DISCUSSION 
This is the first study exploring the association 
between a pre-transplantation INTERMED 
evaluation and post-transplantation 
immunosuppressant therapy adherence among 
patients with kidney, heart, lung and liver 
transplants. Using an original approach, adherence 
to all dosages of immunosuppressive medication 
(cyclosporine or tacrolimus) was monitored and 
compiled longitudinally for 12 months post-
transplant. All prescribed dosage adjustments and 
non-monitored periods due to frequent 
hospitalizations were taken into account to reflect 
daily adherence as accurately as possible. 
As previously shown, INTERMED identifies patients 
at risk for an impaired HRQOL outcome following 
transplantation.
16
 The INTERMED scores and the 
distribution of complex versus non-complex 
transplant patients observed in our study were quite 
comparable to those found in other populations of 
diabetic patients and orthopaedic trauma individuals 
at tertiary care centres.
41,42
 In our population, 
complex patients had significantly higher scores 
than non-complex patients, especially regarding 
psychological (5.7 versus 2.1) and social domains 
(4.9 versus 2.0), while differences in biological (8.2 
versus 6.9) and health care (5.4 versus 4.3) 
domains, although significant, were less 
pronounced and therefore less useful in 
discriminating complex versus non-complex 
patients. Furthermore, as adherence in chronic 
patients is known to be influenced by psychological 
disturbances
43,44
 and social problems
45
, the 
appropriateness of using a biopsychosocial tool, 
such as the INTERMED, rather than a psychosocial 
tool as the above mentioned SIPAT
14,15
 has to be 
questioned. The SIPAT study
14
 showed a non-
significant correlation between high SIPAT scores 
and medication nonadherence, therefore research 
on this question has to continue.  
The exploratory results about medication 
adherence, as measured electronically, show that 
complex patients identified by INTERMED tend to 
have lower medication adherence after 
transplantation vs. non-complex patients. However, 
due to the small sample size of this study, this 
finding did not reach statistical significance and thus 
the hypothesis that complex patients have lower 
adherence needs to be explored further. We also 
noted that withdrawals seemed to occur earlier in 
complex patients compared to non-complex patients 
(within the first month versus after 5 to 6 months, 
respectively). Whether withdrawing is the first sign 
of lower adherence to medication needs to be 
clarified, as the literature shows that the first 
rejection tends to occur sooner in patients with 
lower adherence than in patients with stable 
adherence.
20,21
 
This study has several limitations. First, it had a 
relatively high exclusion rate; several patients had 
to be excluded for medical, organizational and 
logistic reasons because the wait time between 
eligibility for transplantation and actual transplant is 
long. The complex implementation of the protocol 
requires rigorous interdisciplinary collaboration 
 
Table 2. Differences in sociodemographic and medical variables between included and excluded patients at baseline 
 Inclusions (N=32) Exclusions (N=20) p 
age M (SD) 48 years (11) 52 years (11) 0.160
1 
Sex ratio   0.350
2 
% Men 20 (62.5%) 15 (75.5%)  
% Women 12 (37.5%) 5 (25.0%)  
Organ (%)   0.210
2 
Lung 7 (21.9%) 3 (15.0%)  
Heart 8 (25.0%) 3 (15.0%)  
Kidney 16 (50.0%) 10 (50.0%)  
Liver 1 (3.1%) 4 (20.0%)  
Number of transplantations (%)   0.818
2 
First 28 (87.5%) 17 (85.0%)  
Second 3 (9.4%) 1 (5.0%)  
Third 1 (3.1%) 1 (5.0%)  
 Missing data 0 (0.0%) 1 (5.0%)  
Work status (%)   0.198
2 
Employed 18 (56.3%) 7 (35.0%)  
Unemployed 13 (40.6%) 13 (65.0%)  
 Missing data 1 (3.1%) 0 (0%)  
Social status (%)   0.453
2 
Living alone 7 (21.9%) 7 (35.0%)  
Living with a partner 24 (75.0%) 13 (65.0%)  
Missing data 1 (3.1%) 0 (0%)  
Intermed M (SD)    
Biological 7.3 (1.2) 7.3 (1.4) 0.688
1 
Psychological 3.3 (2.6) 4.7 (2.8) 0.062
1 
Social 3.0 (2.1) 3.1 (2.2) 0.824
1 
Health Care 4.6 (1.2) 5.0 (1.4) 0.232
1 
Sumscore 18.3 (5.2) 20.2 (5.1) 0.218
1 
1
Mann – Whitney – U – Test  
2
Pearson’s chi square 
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between pharmacy, liaison psychiatry and the 
different transplantation subspecialties, and 
accounts for the fact that 30% of the patients were 
excluded for logistical reasons. Only 1 out of 5 liver 
SOT recipients were included because after 
initiating the study, the Geneva University Hospital 
became the sole centre for liver transplantation in 
the French speaking part of Switzerland, thus 
making follow up in Lausanne impossible. Other 
studies
23,46,47
 assessing adherence and 
psychosocial factors in post-transplant patients 
reported similarly high exclusion rates (between 
37.3% and 58.3%). Moreover, the fact that 
candidates for liver transplantation, who are usually 
complex due to a high prevalence of substance 
abuse and its psychosocial consequences, were 
underrepresented, might have decreased the case 
complexity of the sample and decreased the 
statistical power of the INTERMED with regard to 
medication adherence. Second, the time between 
the first patient enrollment and the study publication 
is around ten years, which could call into question 
the validity of our conclusions. However, because 
immunosuppressant treatments have not 
experienced major changes in the last decade
48
, 
this risk is mitigated. Third, we did not evaluate the 
association between deviations in timing and the 
INTERMED complexity score. We decided to do so 
because of two reasons: 1) more than two-thirds of 
the included patients were taking tacrolimus, which 
elimination half-life is long (43 hours), and 2) we 
focussed on whether or not tacrolimus or 
cyclosporine were taken daily with the right 
regimen, taking precisely into account all the 
different dosages patients were taking as well as all 
the regimen changes that happened during the 12-
month post-transplant. In a further study it would be 
important to investigate the association between the 
pre-transplant INTERMED score, 
immunosuppressant timing and plasma 
immunosuppressant levels. Indeed, timing could be 
an interesting proxy to understand in more detail the 
way patients self-manage their immunosuppressant 
treatment at home. This might be analysed as a 
very early trigger for nonadherence, if indeed one 
can show that timing nonadherence is a predictor of 
taking nonadherence over time. Fourth, the 
pharmacists were blinded to the INTERMED score 
but not to the medication electronic adherence data, 
as they provided monthly feedback to the patients. 
However, this minimal intervention was the same for 
complex and non-complex patients, which should 
prevent an intervention bias between the two 
groups. 
The study sample size was insufficient to achieve 
conclusive results. The fact that adherence is lower 
in complex patients requires to be further 
investigated because this information is crucial for 
clinical care both pre- and post-transplantation. 
Indeed, as in other populations, complex patients 
identified by means of the INTERMED might benefit 
from early and targeted psychosocial 
interventions.
29
 Adherence might be increased by 
interventions such as patient-centred, 
interprofessional medication adherence 
programmes dedicated to complex patients. 
 
CONCLUSIONS 
This exploratory study gives insight into the complex 
field of interdisciplinary research in Organ 
Transplantation. Although the results did not reach 
statistical significance, they did suggest that the 
concept of biopsychosocial complexity and the use 
of the INTERMED in transplantation medicine could 
 
Table 3. Differences between complex (INTERMED>20) and non-complex patients (INTERMED≤20) 
 Complex ( N=11) Non-complex (N=21) p 
Age M (SD) 50 years (12) 47 years (11) 0.366
1 
Sex ratio   0.844
2 
% Men 6 (54.5%) 14 (66.6%)  
% Women 5 (45.4%) 7 (33.3%)  
Organ (%)   0.874
2 
Lung 2 (18.2%) 5 (23.8%)  
Heart 4 (36.4%) 4 (19.0%)  
Kidney 5 (45.5%) 11 (52.4%)  
Liver 0 (0.0%) 1 (4.8%)  
Time on waiting list 6 months (SD 11) 3 months (SD 5) 0.386
1 
Number of transplantations (%)   0.317
2 
First 9 (81.8%) 19 (90.5%)  
Second 2 (18.2%) 1 (4.8%)  
Third 0 (0.0%) 1 (4.8%)  
Work status (%)   0.037
2 
Employed 4 (36.4%) 15 (71.4%)  
Unemployed 6 (54.5%) 6 (28.6%)  
 Missing data 1 (9.0%) 0 (0.0%)  
Social status (%)   0.121
2 
Living alone 4 (36.4%) 3 (14.3%)  
Living with a partner 6 (54.5%) 18 (85.7%)  
Missing data 1 (9.1%) 0 (0.0%)  
Intermed M (SD)    
Biological 8.2 (0.8) 6.9 (1.1) 0.003
1 
Psychological 5.7 (2.3) 2.1 (1.8) 0.000
1 
Social 4.9 (1.7) 2.0 (1.4) 0.000
1 
Health Care 5.4 (0.9) 4.3 (1.2) 0.022
1 
Sumscore 24.2 (2.7) 15.4 (3.1) 0.000
1 
1
Mann–Whitney U Test  
2
Pearson’s chi squared test 
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be a way to identify pre-transplant patients at risk 
for post-transplant non-adherence. If such results 
are confirmed by larger studies, early and targeted 
interventions could be designed to prevent rejection 
by addressing adherence before transplantation 
with complex patients.  
Another question that could be addressed in future 
studies is whether the use of a nonspecific 
biopsychosocial instrument such as the INTERMED 
is the most efficient way of detecting adherence 
problems in the transplant population. As transplant 
patients generally are highly morbid and in need of 
complex health care, a more specific instrument that 
focuses on psychopathology and social issues 
might be more appropriate. Yet one has to be 
aware, that splitting psychosocial problems from 
medical factors increases fragmentation of care.
49
  
The study design points furthermore to the specific 
challenge of data collection for researchers working 
in interdisciplinary transplantation teams. Rigorous 
communication is a basic requirement for 
successful interdisciplinary research. Moreover, the 
fact that transplantation dates are unpredictable and 
therefore data collection post-transplant cannot be 
planned might lead to investigators who are 
overburdened with their dual responsibilities as 
clinicians and researchers. To prevent the loss of 
precious data in a population with a naturally high 
risk of exclusion and withdrawal, future studies 
gathering interprofessional pre- and post-transplant 
data should keep this aspect in mind when 
designing the protocol. 
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Figure 2. Medication adherence: implementation of all dosages of cyclosporine/tacrolimus during the 12-month period 
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